Ubrolexin | the best for Treatment of mastitis | in cows

Description

Shipping

Reviews (0)

Vendor Info

More Products

For Veterinary Use Only.

Ubrolexinis an Intramammary suspension for the Treatment of clinical mastitisin dairy cows let’s know more about the product with Byttara

composition

Each intramammary syringe of 10 g (12 ml)Ubrolexin contains:

Indications:

Ubrolexin for the Treatment of clinical mastitis in lactating dairy cows caused by bacteria susceptible to the combination of cefalexin and kanamycin such as Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, Escherichia coli and coagulase-negative staphylococci.

Target species:

Cattle (lactating dairy cows).

Contraindication:

-Do not use in lactating dairy cows with a known hypersensitivity to cefalexin and/or kanamycin.
-Do not use in non-lactating cattle.
-Do not use where resistance is known or likely to occur.

Dosage routes and method of administration:

Ubrolexin For intramammary use only.

-Treat the infected quarter(s) of the udder twice in 24 hours.
-Use the contents of one syringe per quarter per treatment.
-Each syringe is for single use only.
-Before infusion the udder should be milked out completely, the teat should be thoroughly cleaned and disinfected and care should be taken to avoid any contamination.

Withdrawal periods:

Meat and offals: 10 days.
Milk: 5 days.

Special storage precautions:

Keep Ubrolexin out of the reach and sight of children.
Do not store above 30° C.
Once a syringe has been opened use the content immediately.

Special warnings

-precaution for use in animals, recommendations for prudent use:
–Ubrolexin should be used for the treatment of clinical mastitis only.
-Use of Ubrolexin should be based on susceptibility testing of the bacteria isolated from the animal.
-If this is not possible, therapy should be based on local (regional and farm level) epidemiological information about the susceptibility of the target bacteria as well as by taking into account official national antimicrobial policies.
-Inappropriate use of Ubrolexin may increase the prevalence of bacteria resistant to cefalexin and kanamycin and may decrease the effectiveness of treatment with other cephalosporins or aminoglycosides due to the potential for cross-resistance.

User warnings:

Penicillins and cephalosporins may cause hypersensitivity (allergic reactions) following injection,
inhalation, ingestion or skin contact.
1. Do not handle Ubrolexin if you know you are sensitized, or if you have been advised not to work
with such preparations.

2. Take all recommended precautions. Handle this product with great care to avoid exposure by accidental contact with the skin.
It is recommended to wear protective gloves when handling or administering the product. Wash exposed skin after use.

3. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning.
Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.